Sun Pharma Advanced Research Company (SPARC) Q3 25/26 earnings summary

Executive summary

• Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025.

• Financial statements reviewed by independent auditors with no material misstatements identified.

Financial highlights

• Q3 consolidated revenue from operations: ₹845 lakhs, down from ₹1,491 lakhs in Q3 FY24.

• Q3 consolidated net loss: ₹8,042 lakhs, compared to ₹7,951 lakhs loss in Q3 FY24.

• Nine-month consolidated net loss: ₹20,814 lakhs, compared to ₹28,274 lakhs loss in the prior year period.

• Basic and diluted loss per share for Q3: ₹2.48, compared to ₹2.45 in Q3 FY24.

Outlook and guidance

• Company and group continue as a going concern, supported by a promoter group entity.

• Monitoring ongoing regulatory changes and their financial impact.